<code id='F17AD5A5DA'></code><style id='F17AD5A5DA'></style>
    • <acronym id='F17AD5A5DA'></acronym>
      <center id='F17AD5A5DA'><center id='F17AD5A5DA'><tfoot id='F17AD5A5DA'></tfoot></center><abbr id='F17AD5A5DA'><dir id='F17AD5A5DA'><tfoot id='F17AD5A5DA'></tfoot><noframes id='F17AD5A5DA'>

    • <optgroup id='F17AD5A5DA'><strike id='F17AD5A5DA'><sup id='F17AD5A5DA'></sup></strike><code id='F17AD5A5DA'></code></optgroup>
        1. <b id='F17AD5A5DA'><label id='F17AD5A5DA'><select id='F17AD5A5DA'><dt id='F17AD5A5DA'><span id='F17AD5A5DA'></span></dt></select></label></b><u id='F17AD5A5DA'></u>
          <i id='F17AD5A5DA'><strike id='F17AD5A5DA'><tt id='F17AD5A5DA'><pre id='F17AD5A5DA'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:5668
          Sammy Kimball for STAT

          Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

          advertisement

          For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Diagnostic tests are hitting their mathematical limits
          Diagnostic tests are hitting their mathematical limits

          Worriedaboutyourhealth?Youcannowavailyourselfofnoninvasivediagnosticsthatclaimtoscreenforrarebirthde

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Disappointing trial forces Pfizer to pivot on obesity medicine plans

          MarkLennihan/APPfizeronFridaysaiditwasstoppingdevelopmentofatwice-dailyoralobesitymedicationafteranu